DGAP-News
MOLOGEN AG: Public rights offering of convertible bonds with purchase guarantee by major shareholder
DGAP-News: MOLOGEN AG / Key word(s): Corporate Action
MOLOGEN AG: Public rights offering of convertible bonds with purchase
guarantee by major shareholder
21.12.2016 / 21:02
The issuer is solely responsible for the content of this announcement.
MOLOGEN AG: Public rights offering of convertible bonds with purchase
guarantee by major shareholder
21.12.2016 / 21:02
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
MOLOGEN AG: Public rights offering of convertible bonds with purchase
guarantee by major shareholder
- Issue volume: EUR4.99 million, maturity of 8 years
- Conversion price set at EUR1.60
- Coupon of 6% p.a.
- Expected subscription period: December 28, 2016 to January 13, 2017
Berlin, December 21, 2016 - The Executive Board of the biotechnology
company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today resolved, with the
approval of the Supervisory Board, to launch a convertible bond issue with
an aggregate face value of up to EUR4.99 million and a maturity of January
19, 2025 through partial utilization of the authorization granted at the
general meeting of the company on August 13, 2014 ("convertible bond
2017/2025"). The bonds are to be offered to existing shareholders by way of
a prospectus-exempt public rights offering. Furthermore, any securities
that are not subscribed are to be used as part of an international private
placement. Shareholders will additionally be granted the option of buying
any bonds that are not subscribed by other shareholders (so-called
oversubscription). However, in principle, shareholders have no legal right
for allocation of such bonds as part of the oversubscription. Global
Derivative Trading GmbH ("GDT"), the major shareholder of MOLOGEN AG,
made a binding commitment to the company to purchase at least 299,999
partial bonds in total - representing around 60% of the convertible bond
2017/2025 (or, if less non-subscribed partial bonds should be available,
the largest possible number available). Following this purchase guarantee,
the company has assured GDT the allocation of a corresponding number of
partial bonds and, in addition, granted a right of first access to all
further non-subscribed bonds.
With regard to the terms of the convertible bond, MOLOGEN essentially based
these on those of the convertible bonds issued in November 2016 and taken
up in full by GDT. Thus, the company has responded to the wish expressed by
shareholders at the time when the last measure was taken that the company
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER
JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
MOLOGEN AG: Public rights offering of convertible bonds with purchase
guarantee by major shareholder
- Issue volume: EUR4.99 million, maturity of 8 years
- Conversion price set at EUR1.60
- Coupon of 6% p.a.
- Expected subscription period: December 28, 2016 to January 13, 2017
Berlin, December 21, 2016 - The Executive Board of the biotechnology
company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today resolved, with the
approval of the Supervisory Board, to launch a convertible bond issue with
an aggregate face value of up to EUR4.99 million and a maturity of January
19, 2025 through partial utilization of the authorization granted at the
general meeting of the company on August 13, 2014 ("convertible bond
2017/2025"). The bonds are to be offered to existing shareholders by way of
a prospectus-exempt public rights offering. Furthermore, any securities
that are not subscribed are to be used as part of an international private
placement. Shareholders will additionally be granted the option of buying
any bonds that are not subscribed by other shareholders (so-called
oversubscription). However, in principle, shareholders have no legal right
for allocation of such bonds as part of the oversubscription. Global
Derivative Trading GmbH ("GDT"), the major shareholder of MOLOGEN AG,
made a binding commitment to the company to purchase at least 299,999
partial bonds in total - representing around 60% of the convertible bond
2017/2025 (or, if less non-subscribed partial bonds should be available,
the largest possible number available). Following this purchase guarantee,
the company has assured GDT the allocation of a corresponding number of
partial bonds and, in addition, granted a right of first access to all
further non-subscribed bonds.
With regard to the terms of the convertible bond, MOLOGEN essentially based
these on those of the convertible bonds issued in November 2016 and taken
up in full by GDT. Thus, the company has responded to the wish expressed by
shareholders at the time when the last measure was taken that the company
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte